JP2014517038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517038A5 JP2014517038A5 JP2014515934A JP2014515934A JP2014517038A5 JP 2014517038 A5 JP2014517038 A5 JP 2014517038A5 JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014515934 A JP2014515934 A JP 2014515934A JP 2014517038 A5 JP2014517038 A5 JP 2014517038A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- wound
- skin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010052428 Wound Diseases 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- 206010072170 Skin wound Diseases 0.000 claims description 14
- 230000029663 wound healing Effects 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 206010073306 Exposure to radiation Diseases 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 230000037311 normal skin Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 238000000034 method Methods 0.000 description 26
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496472P | 2011-06-13 | 2011-06-13 | |
| US61/496,472 | 2011-06-13 | ||
| US201161528053P | 2011-08-26 | 2011-08-26 | |
| US61/528,053 | 2011-08-26 | ||
| PCT/US2012/042165 WO2012174056A1 (en) | 2011-06-13 | 2012-06-13 | Mitigation of cutaneous injury with il-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517038A JP2014517038A (ja) | 2014-07-17 |
| JP2014517038A5 true JP2014517038A5 (enExample) | 2015-07-30 |
| JP6005736B2 JP6005736B2 (ja) | 2016-10-12 |
Family
ID=47357436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515934A Active JP6005736B2 (ja) | 2011-06-13 | 2012-06-13 | Ｉｌ−１２を用いる皮膚損傷の軽減 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9925246B2 (enExample) |
| EP (1) | EP2718456B1 (enExample) |
| JP (1) | JP6005736B2 (enExample) |
| CA (1) | CA2839261A1 (enExample) |
| WO (1) | WO2012174056A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3484500A4 (en) * | 2016-07-18 | 2020-01-08 | Neumedicines, Inc | USE OF IL-12 AS A REPLACEMENT IMMUNOTHERAPEUTIC |
| JP7045671B2 (ja) * | 2018-11-12 | 2022-04-01 | 有限会社バイオ研 | 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材 |
| JP7448137B2 (ja) * | 2020-03-10 | 2024-03-12 | 日本ゼトック株式会社 | アクチン重合促進剤 |
| CA3220398A1 (en) * | 2021-07-30 | 2023-02-02 | Geoffrey Gurtner | Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5780597A (en) | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
| US5573764A (en) | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| JP2000510813A (ja) | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| US5853714A (en) | 1995-03-27 | 1998-12-29 | Genetics Institute, Inc. | Method for purification of IL-12 |
| AU761520B2 (en) * | 1998-09-15 | 2003-06-05 | Genetics Institute, Llc | Treatment of Kaposi's Sarcoma with IL-12 |
| US7052685B1 (en) * | 1998-10-15 | 2006-05-30 | Trustees Of The University Of Pennsylvania | Methods for treatment of cutaneous T-cell lymphoma |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| US7763256B2 (en) * | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| AU2003303384A1 (en) * | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
| EP1641431B1 (en) * | 2003-07-03 | 2018-01-10 | University Of Southern California | Uses of il-12 for reducing the toxicity of chemo- and/or radio-therapy |
| US7939058B2 (en) * | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
| ATE526057T1 (de) | 2004-08-20 | 2011-10-15 | Glaxosmithkline Llc | Wundheilung durch verabreichung von menschlichem il-18 |
| WO2008067042A2 (en) | 2006-10-10 | 2008-06-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Modeling wound healing |
| US20100330046A1 (en) * | 2009-05-21 | 2010-12-30 | Stratatech Corporation | Human skin substitutes expressing il-12 |
-
2012
- 2012-06-13 WO PCT/US2012/042165 patent/WO2012174056A1/en not_active Ceased
- 2012-06-13 CA CA2839261A patent/CA2839261A1/en not_active Abandoned
- 2012-06-13 US US14/125,887 patent/US9925246B2/en active Active
- 2012-06-13 EP EP12801163.2A patent/EP2718456B1/en active Active
- 2012-06-13 JP JP2014515934A patent/JP6005736B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| HRP20120349T1 (hr) | Formulacija glatiramer acetata smanjenog volumenai postupci davanja | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| JP2013542185A5 (enExample) | ||
| JP2014528901A5 (enExample) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| GB2496794A (en) | Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract | |
| EP4477267A3 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
| RU2015103107A (ru) | Комбинированная композиция | |
| JP2014139255A5 (enExample) | ||
| JP2017501154A5 (enExample) | ||
| Jing et al. | Effects of 180 mT static magnetic fields on diabetic wound healing in rats | |
| BR112013018365A2 (pt) | "peptídeos derivados da lactoferrina humana, uso dos mesmos e composição farmacêutica" | |
| MX379191B (es) | Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension. | |
| François et al. | Synergistic effect of human bone morphogenic protein-2 and mesenchymal stromal cells on chronic wounds through hypoxia-inducible factor-1 α induction | |
| FI3648788T3 (fi) | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää | |
| SG10201908089VA (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| JP2013520447A5 (enExample) | ||
| JP2003528919A5 (enExample) |